Our finding that individuals with high levels of adiponectin have a different risk factor profile (less hypertension, diabetes, and obesity; older; and frail White women) and metabolomic profile supports the hypothesis that the pathogenesis may differ and thus the response to therapy may also differ. This evidence concerns the gene ADIPOQ and obesity disorder.